

Computational methods for integrative omics and relation discovery between biomedical entities





Feb 11, 2016

Karan Uppal (PhD) and Sophia A. Banton (MS, PhD
candidate)

Clinical Biomarkers Laboratory
Emory University School of Medicine

Learning Objectives

- Data-driven methods for integrating paired – omics data and visualizing associations (Karan Uppal)
- Knowledge-driven methods for integrating paired – omics data (Sophia Banton)




Data sources to support healthcare decision making and facilitate precision medicine

Introduction: A Systems Biology Framework

- The goal of **Systems Biology**:
 - Systems-level understanding of biological systems
 - Analyze not only individual components, but their interactions as well and emergent behavior




Exposures
Internal measurements
Disease states




Systems Biology
“Integrative approach in which scientists study pathways and networks will touch all areas of biology, including drug discovery”

C. Henry and C. Washington

Dissecting the Biological system via -omics




Dissecting the Biological system via -omics



“Information Overload”: >10,000 variables per –omics experiment

Methods of omics integration



Meta-dimensional analysis can be divided into three categories. **a** | Concatenation-based integration involves combining data sets from different data types at the raw or processed data level before modelling and analysis. **b** | Transformation-based integration involves performing mapping or data transformation of the underlying data sets before analysis, and the modelling approach is applied at the level of transformed matrices. **c** | Model-based integration is the process of performing analysis on each data type independently, followed by integration of the resultant models to generate knowledge about the trait of interest. miRNA, microRNA; SNP, single-nucleotide polymorphism.

Data-driven methods for integration

Paired integrative –omics analysis

- Discover networks of associations or correlated variables (genes, proteins, metabolites, microbiome, epigenetic alterations, clinical variables, etc.) from paired –omics data measured across same samples
 - Univariate or multivariate regression
 - Example: explaining protein abundance with respect to gene expression
- Determine if different –omics data point to same disease mechanism
- Generate novel hypotheses for further investigation

Metabolomics data (n subjects X p metabolites)

	M1	M2	-	Mn
Subject1	199	19	-	100
Subject2	10	40		90
-	-	-		-
SubjectN	50	30	-	20

Transcriptomics data (n subjects X q genes)

	G1	G2	-	Gn
Subject1	19	19	-	100
Subject2	10	40	-	90
-	-	-	-	-
SubjectN	10	40	-	50

Association matrix

	G1	G2	-	Gn
M1	0.4	0.9	-	0.3
M2	0.7	0.1	-	0.5
M3	0.1	0.6		0.8


Univariate

- Pearson Correlation
- MetabNet (Uppal2015)


Multivariate

- PLS, CCA, sparse PLS
- mixOmics (Cao 2009)


Workflow




Pathway enrichment




Relevance networks



Clustering



Targeted investigation (e.g.: Arginine x Transcriptome)



Metabolomics data (n subjects X p metabolites)

	M1	M2	-	Mn
Subject1	199	19	-	100
Subject2	10	40		90
-	-	-		-
SubjectN	50	30	-	20

Microbiome data (n subjects X q bacterial species)

	B1	B2	-	Bn
Subject1	19	19	-	100
Subject2	10	40	-	90
-	-	-	-	-
SubjectN	10	40	-	50

Association matrix

	B1	B2	-	Bn
M1	0.4	0.9	-	0.3
M2	0.7	0.1	-	0.5
M3	0.1	0.6		0.8

Univariate


- Pearson Correlation
- MetabNet (Uppal2015)

Multivariate


- PLS, CCA, sparse PLS
- mixOmics (Cao 2009)




Pathway enrichment




Relevance networks



Clustering




Targeted investigation



Relevance networks

- What is a network (or graph)?
 - A set of nodes (vertices) and edges (links)
 - Edges describe a relationship (e.g. correlation) between the nodes
- What is a relevance network?
 - Networks of highly-correlated biomedical/clinical entities (Butte 2001; PNAS)
 - Metabolomics x Proteomics, Transcriptomics x Proteomics, Metabolomics x Microbiome, Metabolomics x Clinical variables/phenotypes, etc.
 - Generate a bipartite graph network using an association threshold (e.g. 0.5) to visualize positive or negative associations



Circles: microbial species
Rectangles: metabolome features

Methods for generating relevance networks

- Univariate
 - Pairwise Pearson or Spearman correlation between data from different biomedical/clinical technologies (Butte et al. 2009, Uppal et al. 2015)
 - Software:
 - MetabNet (Uppal 2015; R package for performing pairwise correlation analysis and generating relevance networks)
 - Application: Integration of TCE exposure data and physiological markers with metabolomics (Douglas I. Walker et al. submitted)
- Multivariate
 - Multivariate regression techniques such as partial least squares (PLS), sparse partial least squares regression (sPLS), multilevel sparse partial least squares (msPLS) regression, etc.
 - Software:
 - mixOmics (Cao et al. 2009, Liquet et al. 2012; R package for integration and variable selection using multivariate regression)
 - Applications:
 - Transcriptome x Metabolome (Roede, Uppal et al. 2013)
 - Microbiome x Metabolome (Cribbs, Uppal et al. 2016 in press)



Univariate methods

MetabNet (R package; Uppal 2015)

- Performs pairwise correlation (Pearson or Spearman) or partial correlation analysis to generate association matrix ($p \times q$) and relevance network using the data measure on same N
- Large number of possible associations ($p \times q$)
 - E.g.: 2×10^8 possible associations for 20,000 genes \times 10,000 metabolic features
 - Computationally intensive and hard to interpret results
- More suitable when number of variables in at least one layer (p or q) is small
- Availability: Software and tutorial available on sourceforge (<https://sourceforge.net/projects/metabnet/>)

Case Study 1: Using MetabNet for cross-platform paired integrative analysis. Integration of TCE exposure data and physiological markers with metabolomics
(Walker, Uppal et al. manuscript submitted)

- ◆ Urinary TCE exposure markers
- ◆ Renal biomarkers
- ◆ Immunological markers
- ✓ Unidentifiable halogenated m/z, by isotopic pair
- Identified metabolite
- Unidentifiable m/z; pos mass defect
- Unidentifiable m/z; neg mass defect



Courtesy:
Douglas I. Walker
(manuscript submitted)

Multivariate methods

Generating relevance network using sPLS or msPLS techniques (Cao 2009, Liquet 2012)

- sparse partial least squares (sPLS) regression or multilevel partial least squares (msPLS) method
- One-step procedure for variable selection as well as integration
- Comparison of different multivariate integration techniques showed that sPLS generates (Cao 2009)
- Implemented in the R package mixOmics
- Generates association matrix and allows visualization of associations using bipartite relevance networks (Liquet 2012)

sPLS method

- sPLS is a variable selection and dimensionality reduction method that allows integration of heterogeneous omics data from same set of samples
- Robust approximation of Pearson correlation using regression and latent (principal) variates
- Eg: transcriptome (matrix X) and metabolome (matrix Y) data
where,
matrix X is an $n \times p$ matrix that includes n samples and p metabolites
matrix Y is an $n \times q$ matrix that includes n samples and q genes

Objective function

$\max \text{cov}(X_u, Y_v)$

where

$u_1, u_2 \dots u_H$ and $v_1, v_2 \dots v_H$ are the loading vectors

H is the number of PLS-DA dimensions

A Lasso based optimization is used to select most relevant variables

multilevel sPLS method for experiments with repeated measurements

If X is an $(N \times p)$ intensity matrix, where N is the number of samples and p is the number of m/z features, then

1) Split-up variation:

$$X_w = X_{\text{stimulation}} + X_{\text{time}} + X_{\text{stimulation} \times \text{time}} + X_{\text{residual}} \\ + X_{\text{subject} \times \text{Stimulation}} + X_{\text{subject} \times \text{time}}$$

2) sparse PLS objective function:

$$\max \text{cor}(Y, X_u) \text{var}(X_u)$$

where

Y is the matrix indicating group of each sample


X is the split-up variation

u_1, u_2, \dots, u_H are the loading vectors


H is the number of PLS-DA dimensions

A Lasso based optimization is used to select most relevant variables


Case Study 2: Application of sPLS technique for cross-platform paired integrative analysis. Integration of targeted bile acids measurements and clinical variables (age, BMI, etc.) with metabolomics




A. Association threshold: 0.4



B. Association threshold: 0.5




C. Association threshold: 0.6




D. Pathway analysis (only top two displayed)

Case Study 3: Application of sPLS technique for integrative –omics. Microbiome-Metabolome Wide Association Study of Lung BAL: Global integration of 5930 m/z features with 153 microbial species using sparse Partial Least Squares regression




A. Association threshold: 0.3


Legend
Circles: microbial species
Rectangles: metabolome features



B. Association threshold: 0.4



C. Association threshold: 0.7



D. Using only subset of metabolic features also associated with HIV status (+ve or -ve)

Integrating data from other
sources (e.g. PubMed)

Association mining algorithm for constructing relation trees

$$\text{Pointwise Mutual Information}(t_1, t_2) = v_i * \log_2 \frac{p(t_1 \text{ and } t_2)}{p(t_1) p(t_2)}$$



where

v_i is 1 if term t_2 is present in the controlled vocabulary, 0 otherwise;



$p(t_1)$ is the probability of term 1 in the corpus,

$p(t_2)$ is the probability of term 2 in the corpus, and

$p(t_1 \text{ and } t_2)$ is the probability of co-occurrence of terms 1 and 2 in the corpus




- Patient medical records
- Clinical notes
- Lab results, etc.




Clustering



Relevance networks




Clustering




Metabolites


Genes



Summary



Knowledge-Based Approaches of Data Integration




Sophia A. Banton, Shuzhao Li
Clinical Biomarkers Laboratory
Emory University School of Medicine

Introduction: biological networks


- Types of biological networks:
 - Intra-cellular networks
 - 1. Transcriptional regulatory networks**
 - 2. Metabolic networks**
 3. RNA networks
 4. Protein-protein interaction (PPI) networks
 5. Cell signaling networks
 - Other biological networks
 - Neuronal synaptic connection networks
 - Brain functional networks
 - Ecological food webs
 - Phylogenetic networks
 - Correlation networks (e.g., gene co-expression)
 - Disease – “disease gene” association networks
 - Drug – “drug target” networks

Transcriptional regulation networks and modules

- Model regulation of **gene expression**
 - Gene \rightarrow mRNA \rightarrow protein
- Nodes correspond to genes
- Directed edges correspond to interactions through which the products of one gene affect those of another




Blood Transcription Modules (BTMs)



Blood Transcription Modules (BTM) as a powerful new tool. High quality gene network was first inferred from public transcriptomic data. Context specific subnetworks were derived by intersecting GO, cell types, interactome and bibliome. Gene modules were extracted from these subnetworks by search algorithms that take into account connection density and underlying conditions. KEGG, BioCarta, PID, Reactome and TF targets were integrated as search seeds. These BTM modules can be used as alternative to pathways, and often offer better sensitivities.

Metabolic networks


- Used for studying and modeling **metabolism**
 - Biochemical reactions in cells that allow an organism to carry out essential life functions



Banton et al 2016. *JAALAS* -KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway mapping of marmoset plasma metabolites associated with a change from the NE diet to the purified diet. The black dots represent metabolites in the pathways that were identified by using Mummichog



Metabolic networks

- **Metabolites**
 - Small molecules
 - Macromolecules
- **Metabolic pathways**
 - Series of successive biochemical reactions for a specific metabolic function, e.g., glycolysis, or penicillin synthesis, that convert one metabolite into another



Banton et al 2016. *JAALAS*. Metabolic network activity of plasma amino acid concentrations affected by changes between the baseline, standard, and synthetic diets fed to the common marmoset (*Callithrix jacchus*).


Metabolic model at Genome-scale: need for bioinformatics tools



"And that's why we need a computer."

— Courtesy: Keck Graduate Institute

Mummichog: rewriting metabolomics workflow



A) In the work flow of untargeted metabolomics, the conventional approach requires the metabolites to be identified before pathway/network analysis, while mummichog (blue arrow) predicts functional activity bypassing metabolite identification. **B)** Each row of dots represent possible matches of metabolites from one m/z feature, red the true metabolite, gray the false matches. The conventional approach first requires the identification of metabolites before mapping them to the metabolic network. **C)** mummichog maps all possible metabolite matches to the network and looks for local enrichment, which reflects the true activity because the false matches will distribute randomly.

Case Studies

1. Reanalysis of Snyderome using new tools
2. Galactosemia: GALT transcriptomics and metabolomics integration
3. Formation of memory CD8+ T cells
4. Integration of Metabolomics and Transcriptomics to evaluate the effect pyrimethamine on plasma hemoglobin using Group LASSO

Case Study 1: Reanalysis of Snyderome using new tools

Resource

Cell

Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes

Rui Chen,^{1,11} George I. Mias,^{1,11} Jennifer Li-Pook-Tham,^{1,11} Lihua Jiang,^{1,11} Hugo Y.K. Lam,^{1,12} Rong Chen,^{2,12} Elana Miriami,¹ Konrad J. Karczewski,¹ Manoj Hariharan,¹ Frederick E. Dewey,³ Yong Cheng,¹ Michael J. Clark,¹ Hogune Im,¹ Lukas Habegger,^{6,7} Suganthi Balasubramanian,^{6,7} Maeve O'Huallachain,¹ Joel T. Dudley,² Sara Hillenmeyer,¹ Rajini Haraksingh,¹ Donald Sharon,¹ Ghia Euskirchen,¹ Maya Kasowski,¹ Fabian Grubert,¹ Scott Seki,² Marco Garcia,² Michael A. Blasco,⁹ Peter L. Greenberg,⁴ Phyllis Snyder,¹ Teri E. Klein,¹ Mark Gerstein,^{6,7,8} Kari C. Nadeau,² Hua Tang,¹ and Michael Snyder¹

¹Department of Genetics, Stanford University School of Medicine

²Division of Systems Medicine and Division of Immunology and Allergy, Department of Medicine

³Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine

⁴Division of Hematology, Department of Medicine

⁵Department of Bioengineering

Stanford University, Stanford, CA 94305, USA

⁶Program in Computational Biology and Bioinformatics

⁷Department of Molecular Biophysics and Biochemistry

⁸Department of Computer Science

Yale University, New Haven, CT 06520, USA

⁹Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Center


¹⁰Life Length, Madrid E-28003, Spain

¹¹These authors contributed equally to this work


¹²Present address: Personalis, Palo Alto, CA 94301, USA

*Correspondence: mpsnyder@stanford.edu


DOI 10.1016/j.cell.2012.02.009



Case Study 1: *Mummichog* interpretation of Snyder metabolome






Metabolic Network module corresponding to Linoleate pathway.




Significant Metabolic Pathways during RSV infection ($P < 0.05$). Porphyrin pathway pinpoints the clinical phenotype of anemia.

Gene Pathways from Snyder transcriptome are Consistent with Metabolite Pathways




Case Study 1: Reanalysis of Snyderome using new tools

The transcriptomics signature during RSV infection, using BTMs. Enrichment test was performed within GSEA software, using BTMs as custom gene sets.



Name	NES	NOM p-val
Enriched in monocytes (II) (M11.0)	2.386807	0
Enriched in monocytes (I) (M4.15)	2.08188	0.005102
RIG-1 like receptor signaling (M68)	1.867297	0.00978
Complement Activation (I) (M112.0)	1.948812	0.011086
Enriched in monocytes (III) (M73)	1.932553	0.011905
Cell Activation (IL15, IL23, TNF) (M24)	1.89332	0.012136
Cell Cycle and Growth Arrest (M31)	1.892822	0.016908
Formyl peptide receptor mediated neutrophil response (M11.2)	1.920023	0.021028
RA, WNT, CSF receptors network (Monocyte) (M23)	1.842038	0.022321
Extracellular Matrix, Collagen (M210)	1.76067	0.025316
Signaling in T Cells (I) (M35.0)	1.743513	0.027972
Myeloid cell enriched receptors and transporters (M4.3)	1.942556	0.02849
Inflammatory response (M33)	1.636564	0.029056
Enriched in activated dendritic cells (II) (M165)	1.918629	0.02973
Viral sensing & immunity; irf2 targets network (I) (M111.0)	1.815972	0.03038
Blood Coagulation (M11.1)	1.855351	0.030691
TLR and Inflammatory Signaling (M16)	2.084829	0.031884
Lysosome (M209)	1.678483	0.032407
Innate Antiviral Response (M150)	1.679814	0.033413

Case Study 2: Background



By LHcheM - Own work, CC BY-SA 3.0, <https://commons.wikimedia.org/w/index.php?curid=25944168>

- **Galactosemia** is an autosomal recessive condition that affects an individual's ability to metabolize galactose
- In *Drosophila melanogaster* **dGALT** is the presumed ortholog of the human GALT gene which converts Galactose-1-phosphate to UDP-Galactose
- Genotypes:
 - **Ap2** is the imprecise excision of a p element in the dGALT gene and results in loss of dGalT activity (Knockout).
 - **C2** is the precise excision of the same p element and results in normal GALT activity (Wild-type).


Transcriptome x Metabolome

- Transcriptomics
- 15-20 ug of Larva were used for each RNA extraction and subsequent cDNA synthesis.
- Dye hybridization and microarray were performed using Nimblegen technology.


- Metabolomics
- Human Data
 - 3 Cases and 6 controls
 - Using 19,505 metabolite features
- Fly Data
 - 9 Knockout and 9 Wild-Type
 - Using 9,767 metabolite features

Case Study 2: Transcriptome x Metabolome


Fly Genes



Fly Metabolites



Human Metabolites




Autophagy is essential for effector CD8⁺ T cell survival and memory formation

Xiaojin Xu^{1,5}, Koichi Araki^{1,5}, Shuzhao Li², Jin-Hwan Han¹, Lilin Ye¹, Wendy G Tan¹, Bogumila T Koniczny¹, Monique W Bruinsma³, Jennifer Martinez⁴, Erika L Pearce³, Douglas R Green⁴, Dean P Jones², Herbert W Virgin³ & Rafi Ahmed¹




metabolomics




transcriptomics

Enzymes associated with significant metabolites



Metabolites

Enzymes




2.5.1.56, 2.7.1.91, 2.4.2.9, 2.4.2.8,
1.14.16.4, 1.14.16.5, 3.6.1.22,
2.4.2.1, 2.4.1.80, 3.1.4.35, 2.4.2.4,
2.4.2.7, 2.4.2.14, 2.4.2.11, 2.4.2.12,
3.5.4.17, 2.4.2.19, 1.1.1.94, 3.1.6.8,
3.1.6.1, 4.3.2.2, 1.14.14.1, 3.1.3.4,
3.1.3.5, 3.1.4.46, 2.4.1.141,
1.3.99.13, 3.6.1.5, 3.6.1.6, 3.6.1.9,
3.6.1.8, 2.1.1.1, 3.5.1.9, 2.7.1.1,
2.7.1.8, 3.1.1.4, 2.7.8.-, 3.2.1.18,
2.7.8.2, 2.7.8.5, 2.7.8.8, 1.1.99.4,
1.1.99.5, 2.7.1.74, 2.7.7.14, 3.6.1.29,
3.6.1.19, 3.6.1.17, 2.7.1.138,
2.4.1.47, 6.3.5.1, 6.3.5.3, 6.3.5.2,
6.2.1.3, 1.1.1.102, 4.1.3.3,
1.14.13.30, 3.2.2.1, 2.5.1.18,
3.5.1.23, 1.13.11.11, 2.6.1.7,
2.7.1.59, 4.1.2.13, 2.4.99.8, 2.4.99.9,
1.3.3.6, 3.1.3.10, 3.2.1.46, 3.2.1.45,
6.3.4.4, 2.2.1.1, 2.2.1.2, 6.3.4.1,
2.7.8.1, 2.7.1.20, 1.7.1.7, 2.4.2.22,
2.3.1.24, 2.7.8.11, 2.7.8.15, 3.5.4.3,
3.1.4.2, 3.5.4.6, 2.7.6.1, 2.6.1.16,
3.1.4.12, 3.1.4.17, 2.4.1.117, 1.2.3.1,
3.5.4.4, 1.4.3.2, 4.1.2.27, 3.1.4.3,
6.1.1.2, 4.2.1.17, 3.2.2.2, 3.1.2.2,
3.2.2.6, 3.2.2.5, 3.5.99.6, 3.2.2.8,
1.1.1.8, 3.7.1.3, 1.13.11.34

Genes



Gpd1l, Kdsr, Ado, Acox1, Gmpr2, Tkt, Alg5,
Alg13, Hprt, Nampt, Gsta4, Gstk1, Gstm1,
Gstm4, Gsto1, Gstp1, Gstp2, Gsst2, Hpgds,
Gfpt1, Adk, Nagk, Dck, Sphk1, Sphk2, Prps1,
Prps2, Cept1, Ept1, Cept1, Cdipt, Plb1, Acot2,
Lpin1, Lpin2, Pde1b, Pde2a, Pde3b, Pde4a,
Pde4d, Pde7a, Pde8a, Pde5a, Arsa, Gba2,
Galc, Bst1, Cd38, Asah1, Asah2, Ada, Ampd1,
Ampd2, Ampd3, Cant1, Enpp1, Itpa, Enpp4,
Aldoa, Aldoc, Sgpl1, Npl, Acsl1, Acsl3, Acsl4,
Acsl5
Gpda, Acox3, Oxla, Gmpr1, T23o, Lox5, Cp4f3,
Cp4fe, Cp19a, Cp1a1, Cp1a2, Cp1b1, Cp237,
Cp238, Cp239, Cp240, Cp254, Cp255, Cp270,
Cp2a4, Cp2a5, Cp2ac, Cp2b9, Cp2ba, Cp2bj,
Cp2ct, Cp2d9, Cp2da, Cp2db, Cp2dq, Cp2j5,
Cp2j6, Cp2s1, Cp2u1, Cp341, Cp3ab, Cp3ad,
Cp3ag, Cp3ap, Cp4b1, Cp4ca, Cp4x1, Cy250,
Tph1, Tph2, Alkmo, Nnmt, Tktl1, Tktl2, Taldo,
Cegt, Pnph, Typh, Apt, Nadc, Sia8a, Siat9,
Gsta1, Gsta2, Gsta3, Gstm2, Gstm5, Gstm6,
Gstm7, Gsto2, Gstt1, Gstt4, Maai, Mgst1,
Mgst3, Aadat, Aatm, Kat1, Kat3, Gfpt2, Hkdc1,
Hxk1, Hxk2, Hxk3, Cerkl, Pcy2, Chpt1, Pggs1,
Gpt, Hrsl3, Pa21b, Pa24a, Pa24b, Pa24d,
Pa24e, Pa24f, Pa2g5, Pa2ga, Pa2gc, Pa2gd,
Pa2ge, Pa2gf, Pa2gx, Pg12a, Plpl9, Aco15,
Acot1, Acot3, Acot4, Acot5, Baat, Bach, Them4,
Lpin3, Lpp1, Lpp2, Lpp3, Lppr2, Lppr3, Lppr4,
Ppc1a, Ppc1b, 5nt1a, 5nt1b, 5nt3a, 5nt3b,
5ntc, 5ntd, Ppap, Gpcp1, Asm, Nsma2, Nsma3,
Nsma, Pde10, Pde11, Pde1a, Pde1c, Pde3a,
Pde4c, Pde7b, Pde8b, Cncg, Cnrg, Pde10,
Pde11, Pde6a, Pde6b, Pde6c, Pde9a, Neur1,
Neur2, Neur3, Neur4, Glcm, Kfa, Acer1, Acer2,
Guad, Gnpi1, Gnpi2, Entp1, Entp8, Entp4,
Entp5, Enpp3, Ap4a, Nud12, Fhit, Kynu, Aldob,
Echa, Echm, Echp, Pur8, Sywc, Sywm, Acbg1,
Acbg2, Acsl6, S27a2, Pura1, Pura2, Nade,
Guaa, Pur4

Enzyme genes significantly enriched towards KO




Expression of genes corresponding to related enzymes are enriched for KO cells, DNA microarray data, GSEA (Gene Set Enrichment Analysis). Nominal $p = 0$, FWER $p = 0.024$.

Case Study 4: Integration of Metabolomics and Transcriptomics to evaluate the effect of subcurative doses of pyrimethamine on plasma hemoglobin in Rhesus macaques using Group LASSO

Experimental Design

- Five macaques were each delivered a sub-curative dose of pyrimethamine at Day 21, and 3-day curative doses commencing at Days 52 and 90, in each case immediately following peripheral blood sampling. This results in two **pre-drug**, three **post-drug**, and two **inter-drug** treatments as indicated.
- Plasma samples were collected over the course of 100 days.



- These correspond to:
 - Time Point 1 = Day 0 (Baseline Sampling Point)
 - Time Point 2 = Day 21
 - Time Point 3 = Day 27
 - Time Point 4 = Day 52
 - Time Point 5 = Day 59
 - Time Point 6 = Day 90
 - Time Point 7 = Day 98


Analysis Summary

- **Question 1:** Are there genes and metabolites that are associated with hemoglobin levels?
- Correlation Analysis
 - 305 metabolites are significantly correlated with Hgb levels
 - 1074 genes are significantly correlated with Hgb levels
- **Question 2:** Are there features that separate subjects based on drug exposure (pre vs. inter vs. post)
- Differential Expression Analysis
 - 1660 metabolites can separate the subjects into *inter* and *post* drug exposure groups
 - 925 genes can separate the subjects into *pre*, *inter* and *post* drug exposure groups
- **Conclusion**
 - The list of potential targets is cumbersome (information overload)

Can a single test answer two questions?

- Which features from both platforms are associated with drug exposure?
- Among those features, which of them are *specifically* associated with hemoglobin levels?

Hybrid concatenation and transformation based integration using Group LASSO (Banton et al.)



Contributions of the method

- Allows integration of multiple omics data types
- The method is not platform specific or dependent
- The method retains functional information provided by pathways
- The method allows prediction of outcomes and thus can be used in the development of clinical biomarkers

Least Absolute Shrinkage and Selection Operator (LASSO)

A popular model selection and shrinkage estimation method (Tibshirani 1995).

The lasso estimator is defined as:

$$\hat{\beta}_\lambda = \underset{\beta}{\operatorname{argmin}} (\|Y - X\beta\|_2^2 + \lambda \sum_{j=1}^p |\beta_j|)$$

Where λ is the tuning parameter

Extended from the lasso penalty, the group lasso estimator is:


$$\hat{\beta}_\lambda = \underset{\beta}{\operatorname{argmin}} (\|Y - X\beta\|_2^2 + \lambda \sum_{g=1}^G \|\beta_{I_g}\|_2)$$

I_g : the index set belonging to the g th group of variables.

The penalty does the variable selection at the group level, belonging to the intermediate between l_1 - and l_2 - type penalty.

It encourages that either $\hat{\beta}_g = 0$ or $\hat{\beta}_{g,j} \neq 0$ for all $j \in \{1, \dots, df_g\}$

Integration with Group LASSO



Where Y is the **hemoglobin** level in each subject

*Model built using cross-validation

Results*: Number of Targets is drastically reduced

<u>Pathway</u>	<u>Number of Genes</u>	<u>Number of Metabolites</u>
Ascorbate and aldarate metabolism (Vitamin C)	5	4
Glycerophospholipid metabolism	53	7
Linoleic acid metabolism	6	6
Cysteine and methionine metabolism	26	11
Porphyryn and chlorophyll metabolism	20	9
Retinol metabolism (Vitamin A)	16	6
Valine, leucine and isoleucine degradation	38	6
<u>Nicotinate and nicotinamide metabolism</u>	<u>18</u>	<u>3</u>
Total features	182	52



*Lambda min = 0.009

Lambda se = 0.1872



Proof of Concept: Correlations between Hgb and significant genes/metabolites selected by Group Pathway Lasso

Pathway: Porphyrin and chlorophyll metabolism (Heme dysregulation in first, second, and eighth steps of biosynthetic pathways)



Step 1: Heme biosynthesis (**ALAS2** gene → **aminolevulinic acid** synthase)



Step 8: Terminal step in Heme biosynthesis (**FECH** gene)






Step 2: Heme biosynthesis (**ALAD** gene)



*Putative database match

Summary: methods of omics integration



Meta-dimensional analysis can be divided into three categories. **a** | Concatenation-based integration involves combining data sets from different data types at the raw or processed data level before modelling and analysis. **b** | Transformation-based integration involves performing mapping or data transformation of the underlying data sets before analysis, and the modelling approach is applied at the level of transformed matrices. **c** | Model-based integration is the process of performing analysis on each data type independently, followed by integration of the resultant models to generate knowledge about the trait of interest. miRNA, microRNA; SNP, single-nucleotide polymorphism.

Acknowledgements

Emory University SOM

Dean P. Jones (Professor, Director of Clinical
Biomarkers Laboratory)

Shuzhao Li (Asst. Professor, Director of
Immunometabolomics)

Douglas I. Walker (TCE study)

Paul A. Dawson (Bile acids study)

Sushma K. Cribbs (HIV study)

Judy Fridovich-keil (GALT study)

MahPIC (Pyrimethamine study)

Members of Clinical Biomarkers Laboratory

Georgia State University, PHI

Ruiyan Luo

Clinical Biomarkers Laboratory



Questions?